Sarah Blagden
Professor of Experimental Oncology
- Lead for Oxford Cancer Trials Office (OCTO)
Recent publications
-
Precision Prevention Studies: A Targeted Approach to Cancer Prevention.
Journal article
Blagden SP. et al, (2025), Cancer Prev Res (Phila), OF1 - OF9
-
A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.
Journal article
Sooi K. et al, (2025), British journal of cancer
-
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.
Journal article
Plummer R. et al, (2025), Cell Rep Med
-
Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.
Journal article
Kazmi F. et al, (2025), Cochrane Database Syst Rev, 3
-
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials.
Journal article
Liu J. et al, (2025), J Clin Oncol